FDA Brief

Warning letters Food

FDA warning letter to

Chill6

High riskIssued Jul 20, 2021Posted Aug 10, 2021Office of Human and Animal Food Operations East – Division 1

FDA told drink maker Chill6 its amino acid beverage is an unapproved new drug sold for anxiety and contains an unsafe additive.

What happened

FDA reviewed the company's website, www.chill6.com, in July 2021 and found it took orders for Chill6 in four flavors. The website said Chill6 lowers anxiety, helps post-traumatic stress disorder, and eases benzodiazepine and alcohol withdrawal, and carried customer testimonials to the same effect. FDA said the product is therefore an unapproved new drug, and also an adulterated and misbranded food because it contains phenibut HCl.

What FDA found

  1. Website statements that Chill6 treats anxiety, PTSD, and alcohol or benzodiazepine withdrawal show the product is intended as a drug.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for those uses, so it is a new drug sold without FDA approval.

    Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. It is intended for conditions a layperson cannot safely treat alone, so it cannot carry adequate directions for use and is misbranded.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. It contains phenibut HCl, which is not an approved food additive, making the product an adulterated food.

    Section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(2)(C)(i)]; section 409(a) [21 U.S.C. 348(a)]
  5. The label calls it a dietary supplement, but the website presents it as a conventional drink, so that label statement is false or misleading.

    Section 403(a)(1) of the Act; section 201(ff)(2)(B)

What FDA wants

FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If the work cannot be finished in that time, the company must say why and give a completion date.

Who should pay attention

  • beverage and supplement brands that sell online with health claims
  • companies using phenibut or other non-approved ingredients
  • contract manufacturers and labelers of supplement drinks
  • retailers and distributors listing such products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk